GLPwatch
Papers (10389)
Page 163 of 174, ranked by citation count.
- Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
- The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
- Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.
- A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist.
- <i>Akkermansia muciniphila</i> and GLP-1-Based Therapies: Bidirectional Interactions and Implications for Type 2 Diabetes and MASLD/MASH.
- Evaluating The Long-Term Cost-Effectiveness Of Liraglutide 1.2 Mg And Exenatide In Patients With Type 2 Diabetes Mellitus.
- Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.
- Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice.
- [Case report: successful treatment with liraglutide in an insulin allergic patient with liver cirrhosis, hepatocellular carcinoma and poor glycemic control using high dose of insulin].
- New Injectable Drug for Type 2 Diabetes.
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials.
- Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.
- Targeting UBE2B-mediated U2AF1 degradation to alleviate endothelial dysfunction in renal ischemia-reperfusion injury: therapeutic potential of semaglutide.
- An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.
- Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
- Association of inflammation with glycemic control, insulin sensitivity, and beta-cell function in diabetic cats.
- [Basal insulin and GLP-1 agonist potentiate each other (interview by Dr. med Dirk Einecke)].
- Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes On Oral Antidiabetic Drugs In Greece.
- Weight Loss, Adverse Effects With GLP-1 Medications May Be Influenced by Genetics.
- Interpreting Post-Discontinuation Trajectories After Semaglutide or Tirzepatide.
- Beyond Patient Factors: Are we Missing the Surgical Context in Comparing Tirzepatide and Semaglutide Post-CABG?
- Commentary on the Risks of Prescription GLP-1 Agonists in Patients on Psychiatric Medications.
- When New Therapies Meet Old Challenges: Tirzepatide-Warfarin Interaction in A Mechanical Mitral Valve Patient.
- Multi-target incretin-based therapeutics: The rise of dual and triple agonists for metabolic disorders.
- Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis.
- A multimodal HPLC stability indicating approach for the estimation of Semaglutide and Tirzepatide in bulk, pharmaceutical dosage forms, and rat plasma: a six-edged sustainability appraisal.
- Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'.
- GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies.
- Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism.
- FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.
- Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO).
- The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives.
- Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism.
- An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes.
- Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
- A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.
- Benefits of Incretin Therapy on Ovarian Function: A Scientific Literature Review.
- Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics.
- Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
- Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).
- Longacting exenatide in diabetes: DURATION-3.
- Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair.
- Effective treatment for fatty liver of liraglutide via inhibiting endoplasmic reticulum stress, oxidative stress and apoptosis pathways.
- [in process].
- [The antidiabetic drug liraglutide lowers risk of cardiac death].
- Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.
- [Degludec/liraglutide] fixed combination as a therapy alternative].
- Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
- Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.
- Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.
- Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling.
- Effect of baseline characteristics on the efficacy of dulaglutide added to basal insulin in Chinese patients with type 2 diabetes: A subgroup analysis of AWARD-CHN3.
- Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
- Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.
- Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset.
- Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.
- [Optimizing treatment of type 2 diabetic patients].
- Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
- London buses: A cardiovascular outcome trial equivalent?